大缺血区域急性卒中的血管内治疗
日本多中心开放标签随机试验纳入203例大血管闭塞且ASPECTS 3~5分的大面积梗死患者,比较血管内治疗联合医疗与单纯医疗。90天改良Rankin量表0~3分比例血管内治疗组31.0% vs 单纯医疗组12.7%(RR 2.43,95%CI 1.35~4.37,P=0.002),但颅内出血更多(58.0% vs 31.4%,P<0.001)。
要点
- 大梗死核心(ASPECTS 3~5分)患者90天良好功能结局血管内治疗组31.0% vs 单纯医疗组12.7%。
- 48小时NIHSS改善≥8分血管内治疗组31.0% vs 单纯医疗组8.8%(RR 3.51)。
- 任何颅内出血血管内治疗组58.0% vs 单纯医疗组31.4%(P<0.001)。
核心结论
- 在日本开展的大面积脑梗死患者试验中,血管内治疗联合医疗较单纯医疗功能结局更好,但颅内出血更多。
研究设计与样本
- 多中心、开放标签、随机临床试验,在日本纳入大血管闭塞且影像显示大面积梗死的患者。
- 梗死面积以阿尔伯塔卒中项目早期CT评分(ASPECTS)3~5分界定(量表0~10分,分值越低梗死越大)。
- 患者按1:1随机分配至血管内治疗联合医疗组或单纯医疗组,在最后已知正常后6小时内或若液体衰减反转恢复图像无早期改变则在24小时内接受干预。
- 两组在适当时使用阿替普酶(0.6 mg/kg体重)。
- 共203例患者随机分组,血管内治疗组101例,单纯医疗组102例;每组约27%患者接受阿替普酶。
主要发现
- 90天改良Rankin量表0~3分比例血管内治疗组31.0% vs 单纯医疗组12.7%(相对危险度2.43;95%CI 1.35~4.37;P=0.002)。
- 改良Rankin量表评分序贯移位总体倾向于血管内治疗。
- 48小时美国国立卫生研究院卒中量表(NIHSS)评分改善至少8分血管内治疗组31.0% vs 单纯医疗组8.8%(相对危险度3.51;95%CI 1.76~7.00)。
- 任何颅内出血血管内治疗组58.0% vs 单纯医疗组31.4%(P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large strokes has not been well studied. METHODS: We conducted a multicenter, open-label, randomized clinical trial in Japan involving patients with occlusion of large cerebral vessels and sizable strokes on imaging, as indicated by an Alberta Stroke Program Early Computed Tomographic Score (ASPECTS) value of 3 to 5 (on a scale from 0 to 10, with lower values indicating larger infarction). Patients were randomly assigned in a 1:1 ratio to receive endovascular therapy with medical care or medical care alone within 6 hours after they were last known to be well or within 24 hours if there was no early change on fluid-attenuated inversion recovery images. Alteplase (0.6 mg per kilogram of body weight) was used when appropriate in both groups. The primary outcome was a modified Rankin scale score of 0 to 3 (on a scale from 0 to 6, with higher scores indicating greater disability) at 90 days. Secondary outcomes included a shift across the range of modified Rankin scale scores toward a better outcome at 90 days and an improvement of at least 8 points in the National Institutes of Health Stroke Scale (NIHSS) score (range, 0 to 42, with higher scores indicating greater deficit) at 48 hours. RESULTS: A total of 203 patients underwent randomization; 101 patients were assigned to the endovascular-therapy group and 102 to the medical-care group. Approximately 27% of patients in each group received alteplase. The percentage of patients with a modified Rankin scale score of 0 to 3 at 90 days was 31.0% in the endovascular-therapy group and 12.7% in the medical-care group (relative risk, 2.43; 95% confidence interval [CI], 1.35 to 4.37; P = 0.002). The ordinal shift across the range of modified Rankin scale scores generally favored endovascular therapy. An improvement of at least 8 points on the NIHSS score at 48 hours was observed in 31.0% of the patients in the endovascular-therapy group and 8.8% of those in the medical-care group (relative risk, 3.51; 95% CI, 1.76 to 7.00), and any intracranial hemorrhage occurred in 58.0% and 31.4%, respectively (P<0.001). CONCLUSIONS: In a trial conducted in Japan, patients with large cerebral infarctions had better functional outcomes with endovascular therapy than with medical care alone but had more intracranial hemorrhages. (Funded by Mihara Cerebrovascular Disorder Research Promotion Fund and the Japanese Society for Neuroendovascular Therapy; RESCUE-Japan LIMIT ClinicalTrials.gov number, NCT03702413.).
引用
- Yoshimura S, Sakai N, Yamagami H, et al. Endovascular Therapy for Acute Stroke with a Large Ischemic Region. N Engl J Med. 2022. PMID: 35138767. doi:10.1056/NEJMoa2118191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。